(5S)-1-methyl-5-pyridin-3-ylpyrrolidin-2-one

CN1[C@@H](CCC1=O)C2=CN=CC=C2

InChI=1S/C10H12N2O/c1-12-9(4-5-10(12)13)8-3-2-6-11-7-8/h2-3,6-7,9H,4-5H2,1H3/t9-/m0/s1

UIKROCXWUNQSPJ-VIFPVBQESA-N

cotinine; (-)-Cotinine; 486-56-6; (S)-Cotinine; Cotinina; Cotininum; (S)-(-)-Cotinine; Cotinine [INN]; Cotinine (-); (S)-1-methyl-5-(pyridin-3-yl)pyrrolidin-2-one; (5S)-1-methyl-5-(pyridin-3-yl)pyrrolidin-2-one; (S)-1-Methyl-5-(3-pyridinyl)-2-pyrrolidinone; 2-Pyrrolidinone, 1-methyl-5-(3-pyridinyl)-, (5S)-; NIH 10498; (5S)-1-methyl-5-pyridin-3-ylpyrrolidin-2-one; CHEBI:68641; K5161X06LL; S-(-)-Cotinine; (-)-Cotinine 100 microg/mL in Acetonitrile; DSSTox_CID_27576; DSSTox_RID_82428; DSSTox_GSID_47576; (5~{S})-1-methyl-5-pyridin-3-yl-pyrrolidin-2-one; BRD4010; BRD-4010; (5S)-1-Methyl-5-(pyridin-3-yl)pyrrolidin-2-one ((-)-Cotinine); 2-Pyrrolidinone, 1-methyl-5-(3-pyridinyl)-, (S)-; SMR000449278; Cotininum [INN-Latin]; SR-01000075768; Cotinina [INN-Spanish]; UNII-K5161X06LL; CCRIS 7625; HSDB 7805; NCGC00093739-04; (5S)-1-methyl-5-(3-pyridinyl)-2-pyrrolidinone; CAS-486-56-6; Prestwick_134; EINECS 207-634-9; MFCD00077696; n-methyl-2-(3-pyridyl)-5-pyrrolidone; BRN 0083099; Spectrum_001984; COTININE [HSDB]; Nicotine EP Impurity C; COTININE [MI]; Prestwick0_000082; Prestwick1_000082; Prestwick2_000082; Prestwick3_000082; Spectrum3_000700; Spectrum4_001793; Spectrum5_000465; NICOTINE IMPURITY C; bmse000577; (-)-Cotinine, 98%; (S)-1-Methyl-5-(3-pyridyl)-2-pyrrolidinone; S(-)-1-Methyl-5-(3-pyridyl)-2-pyrrolidone; (5S)-1-methyl-5-(3-pyridyl)pyrrolidin-2-one; Lopac0_000285; SCHEMBL49060; BSPBio_000004; BSPBio_002459; KBioGR_002368; KBioSS_002550; 5-24-02-00504 (Beilstein Handbook Reference); MLS000758262; MLS001423950; DivK1c_000861; SPECTRUM1500208; SPBio_001943; (-)-Cotinine, >=98%; BPBio1_000006; CHEMBL578211; MEGxp0_001870; DTXSID1047576; ACon1_000202; KBio1_000861; KBio2_002541; KBio2_005109; KBio2_007677; KBio3_001679; NINDS_000861; US8609708, 91 Cotinine; HMS1568A06; HMS1920A14; HMS2051A15; HMS2091G22; HMS2095A06; HMS2232F15; HMS3260J12; Pharmakon1600-01500208; ZINC402766; (-)-Cotinine, analytical standard; HY-B1178; Tox21_111219; Tox21_300615; Tox21_500285; BBL102262; BDBM50370573; NIH-10498; NSC756704; s9339; STL556061; AKOS007930814; Tox21_111219_1; (-)-Cotinine 1.0 mg/ml in Methanol; CCG-100799; CS-4787; LP00285; NC00049; NSC-756704; SDCCGMLS-0066565.P001; SDCCGSBI-0050273.P004; IDI1_000861; NCGC00093739-08; NCGC00093739-13; NCGC00093739-20; NCGC00254396-01; NCGC00260970-01; AC-35718; AS-50387; NICOTINE IMPURITY C [EP IMPURITY]; SBI-0050273.P003; AM20061246; EU-0100285; C 5923; P10066; AB00053721_08; (5S)-1-methyl-5-pyridin-3-yl-pyrrolidin-2-one; A827581; NICOTINE RESINATE IMPURITY C [EP IMPURITY]; Q421177; SR-01000075768-1; SR-01000075768-5; SR-01000075768-6; (-)-1-METHYL-5-(3-PYRIDYL)-2-PYRROLIDINONE; BRD-K94144010-001-04-8; BRD-K94144010-001-05-5; BRD-K94144010-001-09-7; NICOTINE DITARTRATE DIHYDRATE IMPURITY C [EP IMPURITY]; U5H